AID-JUNCT study: GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery

AID-JUNCT study: GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery

AID-JUNCT study: GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery

Findings from a prospective, randomized clinical study

Innovative approaches to combination therapy in type 1 Diabetes

Glycemic control in type 1 diabetes (T1D) remains a challenge, with ~32% of adults in Switzerland achieving an A1c target of <7%. The dual glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs has emerged as promising therapy in T1D. Retrospective studies have shown people with T1D can significantly improve glycemic control with a reduction in insulin dose and body weight when long-acting GLP-1RAs or GIP/GLP-1RAs are added to insulin therapy.

This study will assess glycemic control in people with T1D on a stable dose of long-acting GIP/GLP-1RA (Tirzepatide) as an adjuvant therapy to automated insulin delivery (AID). We are conducting a prospective, parallel, open-label, randomized clinical trial to test the hypothesis that available AID systems combined with GIP/GLP-1RA will lead to safe and more efficacious glycemic control than Standard of Care (SoC) during the assessment period. The outcome of this study will provide unique data about the safety and efficacy of using GIP/GLP1-RA as adjuvant therapy to AID systems.ย 

Collaborations: PD Dr. med. Thomas Zรผger, Chief Physician – Kantonsspital Olten
Main investigator: Prof. Jose Garcia-Tirado, PhD
Funding: Internal funds

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Obesogenic microbiota Project

Obesogenic microbiota Project

Obesogenic microbiota Project

Exploring the connection: obesity, gut microbiome, and metabolic health

Cause and effect relationship between obesity and gut microbiome

Global rises in metabolic diseases such as obesity and diabetes pose severe medical and socio-economic threats, influenced by a variety of both genetic and environmental factors. Chronic inflammation links these diseases, suggesting an impact on the immune system. The human intestinal flora, especially the metabolic products it produces, appear to play a role in the development of obesity and diabetes.

To understand the underlying mechanisms, our project utilizes innovative methods (gnotobiotics, metagenomics and metabolomics) to explore the relationship between gut flora, metabolism and immune function. By unraveling these relationships, we aim to lay the foundation for innovative strategies to prevent and treat these diseases.

Project team: Melanie Scalise, June Stone
Funding:ย SNSF

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Bacterial metabolites modulating Immune Function

Bacterial metabolites modulating Immune Function

Bacterial metabolites modulating Immune Function

Exploring microbial metabolites and immune activation

Unveiling the role of bacterial metabolites in dendritic cell function

The human gut microbiota, a complex and dynamic community of microorganisms residing in our digestive tract, plays a pivotal role in health and disease. Emerging research reveals a fascinating interplay between the gut microbiota, the immune system, and metabolism. The gut microbiome engages in a constant dialogue with immune cells, educating and regulating them, which in turn maintains gut health and guards against pathogens. This project aims to unravel the hidden mechanisms underlying the interactions between bacterial metabolites in the microenvironment and the activation of immune cells, by in particularly focusing on the impact of bacterial metabolites on dendritic cell metabolism and biological function. Preliminary data showed that bacterial metabolites areย highly produced by bacteria expanding logarithmically and it can be sensed by DCs, fueling their activation. A lot of questions have still to be answeredโ€ฆ

Project team: Andrea Celoria
Funding:ย SNSF

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Wound Infection Project

Wound Infection Project

Wound Infection Project

Understanding immune dysregulation in obesity and diabetes

Obesity and diabetes, which are both rapidly increasing in prevalence world-wide, are considered multifactorial in their pathogenesis, including genetic and environmental factors. Amongst the latter, the gut microbiota and bacteria-derived metabolites have been described to contribute to disease development. Obesity and diabetes are both characterized by a chronic low-grade inflammatory state (โ€œmetaflammationโ€). However, despite the chronic immune activation, obese and diabetic patients are considered immunosuppressed leading to an increased risk for and inferior outcome during infections. This results in increased morbidity and mortality.ย 

The mechanisms leading to immune dysfunction and increased infections in obesity and diabetes are unclear and the main focus of this project.ย 

Projekt team: Marzia Burgunder, Yousef Maali, Andrea Celoria, Melanie Scalise
Funding: Helmut Horton Foundation

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

The Moonwalk Project

The Moonwalk Project

The Moonwalk Project

Investigating the relationship between glucose values and motion patterns during sleep

Glucose Levels and Sleep Patterns

People with diabetes need to carefully control their blood sugar levels to avoid short and long-term health complications. This can be done using insulin injections, but it also increases the risk of low blood sugar, called hypoglycaemia. Hypoglycaemia often occurs at night and can lead to serious problems such as falls and heart problems. It can also reduce quality of life and cause symptoms like shaking, abnormal breathing, and abnormal movements. Managing diabetes can be especially difficult for elderly people in long-term care due to other health conditions and changes in care providers. The Moonwalk project aims to investigate the possible association between glucose levels and motion patterns during sleep in people with diabetes. To achieve this, a QUMEA radar sensor is mounted on the ceiling to track motion during sleep, and wrist-worn smartwatches are used to collect data on physiological symptoms. Over the course of 10 days, data will be collected from 40 patients. After the end of the study, algorithms will be developed to build a warning system for nocturnal hypoglycaemia.

Project team: Prof. Lilian Witthauer, Prof. Markus Laimer, QUMEA AG

Funding: Diabetes Center Berne Foundation, Innosuisse Innovation Cheque, Von-Tobel Foundation

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland